These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1687500)

  • 21. Lateral diffusion of CD4 on the surface of a human neoplastic T-cell line probed with a fluorescent derivative of the envelope glycoprotein (gp120) of human immunodeficiency virus type 1 (HIV-1).
    Pal R; Nair BC; Hoke GM; Sarngadharan MG; Edidin M
    J Cell Physiol; 1991 May; 147(2):326-32. PubMed ID: 2040664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
    Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
    Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Wu L; Gerard NP; Wyatt R; Choe H; Parolin C; Ruffing N; Borsetti A; Cardoso AA; Desjardin E; Newman W; Gerard C; Sodroski J
    Nature; 1996 Nov; 384(6605):179-83. PubMed ID: 8906795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the human immunodeficiency virus type 1 envelope protein interaction with the CD4 host cell receptor.
    Malvoisin E; Wild F
    J Gen Virol; 1994 Apr; 75 ( Pt 4)():839-47. PubMed ID: 8151300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
    Brighty DW; Rosenberg M; Chen IS; Ivey-Hoyle M
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7802-5. PubMed ID: 1909031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.
    O'Brien WA; Mao SH; Cao Y; Moore JP
    J Virol; 1994 Aug; 68(8):5264-9. PubMed ID: 8035523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment.
    Groenink M; Moore JP; Broersen S; Schuitemaker H
    J Virol; 1995 Jan; 69(1):523-7. PubMed ID: 7983749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1.
    Schutten M; Andeweg AC; Bosch ML; Osterhaus AD
    Scand J Immunol; 1995 Jan; 41(1):18-22. PubMed ID: 7824885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of CD4-gp120 activation intermediates during human immunodeficiency virus type 1 syncytium formation.
    Hart TK; Truneh A; Bugelski PJ
    AIDS Res Hum Retroviruses; 1996 Sep; 12(14):1305-13. PubMed ID: 8891109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120.
    Ardman B; Kowalski M; Bristol J; Haseltine W; Sodroski J
    J Acquir Immune Defic Syndr (1988); 1990; 3(3):206-14. PubMed ID: 2304000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody.
    Perno CF; Cooney DA; Currens MJ; Rocchi G; Johns DG; Broder S; Yarchoan R
    AIDS Res Hum Retroviruses; 1990 Aug; 6(8):1051-5. PubMed ID: 2223241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of antibodies blocking HIV-1 gp 160-sCD4 attachment with virus neutralizing activity in human sera.
    Back NK; Thiriart C; Delers A; Ramautarsing C; Bruck C; Goudsmit J
    J Med Virol; 1990 Jul; 31(3):200-8. PubMed ID: 1697332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naturally occurring soluble CD4 in patients with human immunodeficiency virus infection.
    Peakman M; Senaldi G; Foote N; McManus TJ; Vergani D
    J Infect Dis; 1992 May; 165(5):799-804. PubMed ID: 1349032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.
    Layne SP; Merges MJ; Dembo M; Spouge JL; Conley SR; Moore JP; Raina JL; Renz H; Gelderblom HR; Nara PL
    Virology; 1992 Aug; 189(2):695-714. PubMed ID: 1386485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conjugation of soluble CD4 without loss of biological activity via a novel carbohydrate-directed cross-linking reagent.
    Chamow SM; Kogan TP; Peers DH; Hastings RC; Byrn RA; Ashkenazi A
    J Biol Chem; 1992 Aug; 267(22):15916-22. PubMed ID: 1639820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the noncovalent complex of human immunodeficiency virus glycoprotein 120 with its cellular receptor CD4 by matrix-assisted laser desorption/ionization mass spectrometry.
    Borchers C; Tomer KB
    Biochemistry; 1999 Sep; 38(36):11734-40. PubMed ID: 10512629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody.
    McDougal JS; Kennedy MS; Orloff SL; Nicholson JK; Spira TJ
    J Virol; 1996 Aug; 70(8):5236-45. PubMed ID: 8764033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics of HIV-1 interactions with sCD4 and CD4+ cells: implications for inhibition of virus infection and initial steps of virus entry into cells.
    Dimitrov DS; Willey RL; Martin MA; Blumenthal R
    Virology; 1992 Apr; 187(2):398-406. PubMed ID: 1347667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Daar ES; Li XL; Moudgil T; Ho DD
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6574-8. PubMed ID: 2395859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.